Shuting Xia

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Richard S. Finkel, Claudia A. Chiriboga, Jiri Vajsar et al. · The Lancet · 2016 · 998 citations

Dose-escalation Study, Spinal Cord Injury, Pediatric Spine +6

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · New England Journal of Medicine · 2020 · 924 citations · Full text

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary et al. · The Lancet · 2016 · 730 citations

Dose-ranging Trials, Pharmacology, Hyperlipidemia +7

Nusinersen in later-onset spinal muscular atrophy

Basil T. Darras, Claudia A. Chiriboga, Susan T. Iannaccone et al. · Neurology · 2019 · 256 citations · Full text

N-acetyl galactosamine-conjugated antisense drug to <i>APOC3</i> mRNA, triglycerides and atherogenic lipoprotein levels

Veronica J. Alexander, Shuting Xia, Eunju Hurh et al. · European Heart Journal · 2019 · 218 citations · Full text